{"classes":[{"categories":[{"measurements":[{"groupId":"OG013","spread":"20","value":"16.82"},{"groupId":"OG014","spread":"46","value":"16.93"},{"groupId":"OG015","spread":"148","value":"9.643"},{"groupId":"OG016","spread":"37","value":"10.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"10"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"8"}],"units":"Participants"}],"title":"Total PF-06863135: Cycle 0 Day 1"},{"categories":[{"measurements":[{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.00829.","groupId":"OG000","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.00933 and 0.0136.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.0483 and 0.0484.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"74","value":"0.1654"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.763 and 0.877.","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"11","value":"2.190"},{"groupId":"OG006","spread":"40","value":"3.322"},{"groupId":"OG007","spread":"58","value":"1.182"},{"groupId":"OG008","spread":"17","value":"4.426"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 4.35 and 6.09.","groupId":"OG009","spread":"NA","value":"NA"},{"groupId":"OG010","spread":"26","value":"12.58"},{"groupId":"OG011","spread":"29","value":"17.92"},{"groupId":"OG012","spread":"36","value":"25.53"},{"groupId":"OG013","spread":"14","value":"58.93"},{"groupId":"OG014","spread":"53","value":"93.96"},{"groupId":"OG015","spread":"16","value":"54.78"},{"groupId":"OG016","spread":"45","value":"31.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"8"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"6"}],"units":"Participants"}],"title":"Total PF-06863135: Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.0276.","groupId":"OG001","value":"NA"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.0790.","groupId":"OG002","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 3.88 and 4.36.","groupId":"OG005","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 7.91 and 8.10.","groupId":"OG006","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 3.77 and 10.1.","groupId":"OG007","spread":"NA","value":"NA"},{"groupId":"OG008","spread":"39","value":"13.47"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 32.2 and 42.2.","groupId":"OG010","spread":"NA","value":"NA"},{"groupId":"OG011","spread":"30","value":"76.83"},{"groupId":"OG012","spread":"31","value":"88.92"},{"groupId":"OG013","spread":"21","value":"173.4"},{"groupId":"OG014","spread":"65","value":"148.1"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 71.7 and 77.8.","groupId":"OG016","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"}],"units":"Participants"}],"title":"Total PF-06863135: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG013","spread":"49","value":"4.111"},{"groupId":"OG014","spread":"73","value":"5.054"},{"groupId":"OG015","spread":"92","value":"2.447"},{"groupId":"OG016","spread":"50","value":"3.487"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"10"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"8"}],"units":"Participants"}],"title":"Free PF-06863135: Cycle 0 Day 1"},{"categories":[{"measurements":[{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"1.95","value":"0.0009462"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.261 and 0.618.","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"24","value":"0.7801"},{"groupId":"OG006","spread":"62","value":"1.206"},{"groupId":"OG007","spread":"72","value":"0.3344"},{"groupId":"OG008","spread":"23","value":"1.478"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 2.67 and 3.29.","groupId":"OG009","spread":"NA","value":"NA"},{"groupId":"OG010","spread":"103","value":"4.362"},{"groupId":"OG011","spread":"42","value":"4.909"},{"groupId":"OG012","spread":"33","value":"6.564"},{"groupId":"OG013","spread":"109","value":"11.92"},{"groupId":"OG014","spread":"60","value":"34.13"},{"groupId":"OG015","spread":"12","value":"8.896"},{"groupId":"OG016","spread":"91","value":"11.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"8"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"6"}],"units":"Participants"}],"title":"Free PF-06863135: Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.000.","groupId":"OG002","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.000.","groupId":"OG004","value":"NA"},{"groupId":"OG005","spread":"2.59","value":"0.05280"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 1.51 and 1.57.","groupId":"OG006","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 2.15.","groupId":"OG007","spread":"NA","value":"NA"},{"groupId":"OG008","spread":"49","value":"2.572"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 4.43 and 6.57.","groupId":"OG010","spread":"NA","value":"NA"},{"groupId":"OG011","spread":"113","value":"45.14"},{"groupId":"OG012","spread":"155","value":"34.18"},{"groupId":"OG013","spread":"128","value":"45.63"},{"groupId":"OG014","spread":"63","value":"66.20"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 64.2 and 71.2.","groupId":"OG016","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"}],"units":"Participants"}],"title":"Free PF-06863135: Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"12"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"9"}],"units":"Participants"}],"description":"Area under the concentration curve from time 0 to end of dosing interval (AUCtau) was measured in this outcome measure. Total is free and bound drug in the body.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with relapsed/refractory advanced multiple myeloma (MM) received PF-06863135 at a dose of 0.1 microgram/kilogram (mcg/kg) as an intravenous (IV) infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 1: PF-06863135 0.1 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 0.3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG001","title":"Part 1: PF-06863135 0.3 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG002","title":"Part 1: PF-06863135 1 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG003","title":"Part 1: PF-06863135 3 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 10 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG004","title":"Part 1: PF-06863135 10 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 30 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG005","title":"Part 1: PF-06863135 30 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 50 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG006","title":"Part 1: PF-06863135 50 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 80 mcg/kg as a subcutaneous (SC) injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG007","title":"Part 1: PF-06863135 80 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 130 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG008","title":"Part 1: PF-06863135 130 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 215 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG009","title":"Part 1: PF-06863135 215 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 360 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG010","title":"Part 1: PF-06863135 360 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 600 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG011","title":"Part 1: PF-06863135 600 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1000 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG012","title":"Part 1: PF-06863135 1000 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every week (Q1W) on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG013","title":"Part 1.1: PF-06863135 Priming Cohort Q1W SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every 2 weeks (Q2W) on Day 1 and 15 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG014","title":"Part 1.1: PF-06863135 Priming Cohort Q2W SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with lenalidomide at dose of 15 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG015","title":"Part 1C: PF-06863135 + Lenalidomide SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with pomalidomide at dose of 4 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG016","title":"Part 1D: PF-06863135 + Pomalidomide SC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK parameter analysis set was defined as all enrolled participants treated who had sufficient information to estimate at least 1 of the PF- 06863135 PK parameters of interest. All participants reported under \"Number of Participants Analyzed\" contributed data to the table; however, may not have evaluable data for every row. Here, \"Number Analyzed\" signifies number of participants evaluable at specified rows.","reportingStatus":"POSTED","timeFrame":"0 hours (h) on Day 1 of Cycle (C) 0; 0, 2 and 4h on Day 1 of C1 and C2","title":"Part 1: Area Under the Concentration-Time Profile From Time 0 to End of Dosing Interval (AUCtau)","type":"SECONDARY","unitOfMeasure":"Microgram*day per milliliter"}